APEA NEURO PHARMACOLOGY – LATEST 2025
REVISED QUESTIONS & ANSWERS
Comprehensive Study Guide for APEA Neuro
Pharm Exam
📋 EXAM OVERVIEW
| Detail | Information |
|:|:|
| Exam | APEA Neuro Pharmacology (Advanced Practice Education Associates) |
| Target Audience | Nurse Practitioners (FNPs, AGNPs, PMHNPs) |
| Latest Update | 2025 Revised |
| Format | Multiple-choice, clinical scenarios |
| Key Topics | Parkinson's disease, Alzheimer's, seizures, migraines, stroke/TIA, MS, movement
disorders, CNS medications |
| Status | Verified Questions & Correct Answers |
SECTION 1: PARKINSON'S DISEASE & MOVEMENT DISORDERS
QUESTION 1
What is Parkinson's disease?
A) An autoimmune disease affecting the peripheral nervous system
B) A neurodegenerative disorder affecting dopamine-producing neurons in the substantia nigra
C) A viral infection of the central nervous system
D) A demyelinating disease of the spinal cord
Correct Answer: B
Rationale: Parkinson's disease is a progressive neurodegenerative disorder characterized by
the loss of dopamine-producing neurons in the substantia nigra pars compacta.
QUESTION 2
What is the primary treatment for Parkinson's disease?
,A) Surgical intervention only
B) Medications to control symptoms; there is no cure
C) Physical therapy alone
D) Dietary modifications
Correct Answer: B
Rationale: There is no cure for Parkinson's disease; treatment focuses on managing symptoms
with medications.
QUESTION 3
What is the role of dopamine agonists in Parkinson's treatment?
A) They are used only as a last resort
B) They are administered early and later with Levodopa/Carbidopa to reduce dosages
C) They replace Levodopa entirely
D) They are only effective in the final stages
Correct Answer: B
Rationale: Dopamine agonists are often used early in treatment and can be combined with
Levodopa/Carbidopa to allow for lower doses of Levodopa.
QUESTION 4
What is the function of Levodopa/Carbidopa?
A) Levodopa prevents dopamine breakdown; Carbidopa crosses the blood-brain barrier
B) Levodopa crosses the blood-brain barrier and is converted to dopamine; Carbidopa prevents
premature conversion in the intestines
C) Both drugs cross the blood-brain barrier and act as dopamine agonists
D) Carbidopa is converted to dopamine; Levodopa prevents conversion
Correct Answer: B
Rationale: Levodopa is the precursor to dopamine that crosses the blood-brain barrier.
Carbidopa inhibits the peripheral decarboxylation of levodopa, preventing its premature
conversion outside the brain.
QUESTION 5
What are common side effects of Levodopa/Carbidopa?
, A) Weight gain, hyperglycemia, and hypertension
B) Nausea, vomiting, drowsiness, dyskinesia, orthostatic hypotension, tachycardia, and
psychosis
C) Hepatotoxicity and nephrotoxicity
D) Bradycardia and hypothermia
Correct Answer: B
Rationale: Common side effects include nausea, vomiting, drowsiness, dyskinesia, orthostatic
hypotension, tachycardia, and psychosis.
QUESTION 6
What are MAO-B inhibitors and their purpose?
A) Medications like Selegiline and Rasagiline that help with the 'wearing off' effect of Levodopa
B) Medications that completely replace Levodopa
C) Medications that treat only the tremors of Parkinson's
D) Medications used exclusively for Alzheimer's disease
Correct Answer: A
Rationale: MAO-B inhibitors (selegiline, rasagiline) help manage the "wearing off" effect of
Levodopa by inhibiting the breakdown of dopamine.
QUESTION 7
What is the mechanism of action for COMT inhibitors?
A) They increase dopamine production in the brain
B) They enhance the effect of Levodopa by blocking its breakdown
C) They directly stimulate dopamine receptors
D) They prevent the absorption of Levodopa
Correct Answer: B
Rationale: COMT inhibitors enhance the effect of Levodopa by blocking its breakdown, thereby
prolonging its action.
QUESTION 8
What are the side effects of COMT inhibitors?
REVISED QUESTIONS & ANSWERS
Comprehensive Study Guide for APEA Neuro
Pharm Exam
📋 EXAM OVERVIEW
| Detail | Information |
|:|:|
| Exam | APEA Neuro Pharmacology (Advanced Practice Education Associates) |
| Target Audience | Nurse Practitioners (FNPs, AGNPs, PMHNPs) |
| Latest Update | 2025 Revised |
| Format | Multiple-choice, clinical scenarios |
| Key Topics | Parkinson's disease, Alzheimer's, seizures, migraines, stroke/TIA, MS, movement
disorders, CNS medications |
| Status | Verified Questions & Correct Answers |
SECTION 1: PARKINSON'S DISEASE & MOVEMENT DISORDERS
QUESTION 1
What is Parkinson's disease?
A) An autoimmune disease affecting the peripheral nervous system
B) A neurodegenerative disorder affecting dopamine-producing neurons in the substantia nigra
C) A viral infection of the central nervous system
D) A demyelinating disease of the spinal cord
Correct Answer: B
Rationale: Parkinson's disease is a progressive neurodegenerative disorder characterized by
the loss of dopamine-producing neurons in the substantia nigra pars compacta.
QUESTION 2
What is the primary treatment for Parkinson's disease?
,A) Surgical intervention only
B) Medications to control symptoms; there is no cure
C) Physical therapy alone
D) Dietary modifications
Correct Answer: B
Rationale: There is no cure for Parkinson's disease; treatment focuses on managing symptoms
with medications.
QUESTION 3
What is the role of dopamine agonists in Parkinson's treatment?
A) They are used only as a last resort
B) They are administered early and later with Levodopa/Carbidopa to reduce dosages
C) They replace Levodopa entirely
D) They are only effective in the final stages
Correct Answer: B
Rationale: Dopamine agonists are often used early in treatment and can be combined with
Levodopa/Carbidopa to allow for lower doses of Levodopa.
QUESTION 4
What is the function of Levodopa/Carbidopa?
A) Levodopa prevents dopamine breakdown; Carbidopa crosses the blood-brain barrier
B) Levodopa crosses the blood-brain barrier and is converted to dopamine; Carbidopa prevents
premature conversion in the intestines
C) Both drugs cross the blood-brain barrier and act as dopamine agonists
D) Carbidopa is converted to dopamine; Levodopa prevents conversion
Correct Answer: B
Rationale: Levodopa is the precursor to dopamine that crosses the blood-brain barrier.
Carbidopa inhibits the peripheral decarboxylation of levodopa, preventing its premature
conversion outside the brain.
QUESTION 5
What are common side effects of Levodopa/Carbidopa?
, A) Weight gain, hyperglycemia, and hypertension
B) Nausea, vomiting, drowsiness, dyskinesia, orthostatic hypotension, tachycardia, and
psychosis
C) Hepatotoxicity and nephrotoxicity
D) Bradycardia and hypothermia
Correct Answer: B
Rationale: Common side effects include nausea, vomiting, drowsiness, dyskinesia, orthostatic
hypotension, tachycardia, and psychosis.
QUESTION 6
What are MAO-B inhibitors and their purpose?
A) Medications like Selegiline and Rasagiline that help with the 'wearing off' effect of Levodopa
B) Medications that completely replace Levodopa
C) Medications that treat only the tremors of Parkinson's
D) Medications used exclusively for Alzheimer's disease
Correct Answer: A
Rationale: MAO-B inhibitors (selegiline, rasagiline) help manage the "wearing off" effect of
Levodopa by inhibiting the breakdown of dopamine.
QUESTION 7
What is the mechanism of action for COMT inhibitors?
A) They increase dopamine production in the brain
B) They enhance the effect of Levodopa by blocking its breakdown
C) They directly stimulate dopamine receptors
D) They prevent the absorption of Levodopa
Correct Answer: B
Rationale: COMT inhibitors enhance the effect of Levodopa by blocking its breakdown, thereby
prolonging its action.
QUESTION 8
What are the side effects of COMT inhibitors?
